Related Experiment Video
Updated: Jul 13, 2025
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
[Research Progress and Application of Daratumumab in Non-Multiple Myeloma--Review]
1Department of Hematology, The First Affiliated Hospital of Nanchang University; Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province; Institute of Lymphoma of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Abstract:
Daratumumab is the first CD38 monoclonal antibody drug approved for the treatment of patients with multiple myeloma. It can bind to CD38 expressed by tumor cells, inhibit tumor cell growth and induce myeloma cell apoptosis through a variety of immune-related mechanisms. Meanwhile, CD38 is also expressed in other cells, including regulatory T cells, regulatory B cells and myeloid-derived suppressor cells, which provides a theoretical basis for the treatment of hematological tumor diseases other than non-multiple myeloma diseases. This article reviews the research progress and application of this part.
Insights
Daratumumab, a CD38 monoclonal antibody, effectively treats multiple myeloma by targeting tumor cells. Its action on other immune cells suggests potential for broader hematological cancer therapies beyond multiple myeloma.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Daratumumab is the first approved CD38 monoclonal antibody for multiple myeloma treatment.
- It targets CD38 on myeloma cells, inhibiting growth and inducing apoptosis via immune mechanisms.
- CD38 is also present on regulatory immune cells, indicating broader therapeutic potential.
Conclusions:
- Daratumumab's mechanism of action provides a strong rationale for its use beyond multiple myeloma.
- Further research is warranted to establish the efficacy and safety of Daratumumab in other hematological malignancies.
- Targeting CD38 represents a promising strategy for treating a range of blood cancers.
More Related Videos
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
